Oligonucleotide Synthesis Market Research Report - Forecast till 2030

Oligonucleotide Synthesis Market Research Report: By Product (Oligonucleotide, Reagents and Equipment), By Type (Custom Oligos and Predesigned Oligos), By Application (Therapeutic Applications, Diagnostics, Research and others), By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories and others) - Forecast till 2030

ID: MRFR/LS/1721-HCR | February 2023 | Region: Global | 95 Pages         

Oligonucleotide Synthesis Market Speak to Analyst Request a Free Sample

Oligonucleotide Synthesis Market

The Oligonucleotide Synthesis Market size is projected to grow at a CAGR 16.5% and is expected to reach USD 27,109.8 million in the forecast period

By Product Oligonucleotide Reagents and Equipment
By Type Custom Oligos Predesigned Oligos
By Application Therapeutic Applications Diagnostics Research Others
By End User Academic Research Institutes Pharmaceutical and Biotechnology Companies Diagnostic Laboratories Others
Key Players
Companies Profiled   Thermo Fisher Scientific Inc.   Adtbio Merck - Co. Inc.   Bio-Synthesis Inc.   Eurofins Genomics   GE Healthcare   Horizon Discovery Ltd   Agilent Technologies   Genscript   Kaneka Eurogentec SA   Others
Market Driving Forces   New product launches and R&D Amongst major key Players
Request a Free Sample

Oligonucleotide Synthesis Market Overview

The oligonucleotide synthesis market is expected to gain a market value of USD 27,109.8 million by 2030 at a CAGR of 16.5% over the forecast period of 2022-2030.

The chemical synthesis of relatively short nucleic acid fragments with clearly defined chemical structures is known as oligonucleotide synthesis. The method is beneficial in modern laboratory practice since it gives quick, low-cost access to oligonucleotides manufactured to order with the necessary sequence. It is also helpful for making molecular diagnoses for several disorders, including cancer diagnosis and detecting infectious diseases, including hepatitis and SARS-COV2.

The demand for technological advancements in synthetic chemistry has increased due to the increased use of oligonucleotides. Thus, the development of more modern techniques is being undertaken by numerous biotechnology and pharmaceutical companies. For instance, to develop mini-genes, Integrated DNA Technologies has created oligonucleotides with up to 200 bases employed in mass spectrometry. A strong R&D pipeline, increased clinical trials for novel diseases, and increased oligonucleotide FDA approvals as therapeutic agents are major growth drivers. According to the World Health Organization (WHO), approximately 64,658 clinical trials were conducted globally in 2021, among which the Western Pacific region accounted for 16,860 clinical trials. Such an increase in clinical trials is expected to boost market growth. However, the lack of effective delivery mechanisms for therapeutic genes to reach the intended tumor site is one of the biggest obstacles in cancer gene therapy and antisense therapy.

COVID-19 Analysis

New generations of oligonucleotide therapeutics, including mRNA and DNA vaccines, are currently being developed in response to the rise in coronavirus disease (COVID-19) cases and the urgent need for a viable cure. The major market players’ participation and the use of a variety of oligonucleotide products, including probes and primers, in COVID-19 research have aided in advancing knowledge about the coronavirus. As a result, COVID-19 has had a moderately beneficial effect on the market for oligonucleotide synthesis. However, due to restrictions put in place during the COVID-19 pandemic, oligonucleotide-based medicine sales slightly decreased in 2020.

Market dynamics 

  • Crucial market drivers¬†

The surging government investments for synthesis biology are a crucial market driver. Governmental support helps in technological advancements on the market. The funding and investment by the oligos are beneficial for the high demand of the oligonucleotide synthesis market. Further, the high usage of pharmaceutical companies is a driving factor of the market.

In recent years, biopharmaceutical companies are collecting more than 10000 genetic samples. It is to conduct various clinical trials for the oligonucleotide market. Through this process, treating complex diseases is possible. Including these oligonucleotide components in drugs and medication is raising the demand. All these factors will boost the overall adoption rate.

Further, the expansion of the health sector is another factor driving demand. This advancement is leading to high demand for oligonucleotide synthesis. The new hospitals and health facilities are investing in this component for better treatment of the patients. Additionally, the demand from the developed region is another crucial driver for the oligonucleotide synthesis market. The developed regions such as North America have higher awareness for oligonucleotide synthesis. Better and efficient utilization of this component in gene sequencing is leading to high demand. All these factors of the market will increase the adoption rate of RNA oligonucleotide synthesis. 

  • The market growth opportunities¬†

Demand from emerging economies will bring growth opportunities for the oligonucleotide synthesis market. In recent years, demand from China, India, Japan and Singapore markets is high. This expansion of the market is opening new opportunities for the oligonucleotide synthesis market. China is opening a new facility for RNA oligonucleotide synthesis procedures. To meet the current demand these facilities are helpful. The portfolio and leading oligonucleotide synthesis product will increase revenue rates.

 Further, new approvals for oligonucleotide synthesis drugs are happening in the Asia Pacific region. Especially, spinal muscular diseases are effectively treatable through this component. The approval of new medical products in this region increases the supply rates.

Further, Japan is opening a new facility for research of oligonucleotide synthesis. These labs will develop oligonucleotide synthesis technologies. It is another factor that will turn consumer attention towards the oligonucleotide synthesis market. Governmental support in Singapore is enabling the growth of pharma companies. New establishments and collaborations are rapidly taking place. Altogether, these factors will lead to impeccable opportunities for the oligonucleotide synthesis market. The development of biosynthesis in this region is high. 

  • The market restraint¬†

The issues with therapeutic oligonucleotide synthesis are a market restraint. Awareness of synthetic oligos is high in recent years. The main target of this component is to identify the human genome. These therapeutic oligos are useful to treat infections, cancer, viral disease and rare disease. It is an effective treatment for rare thrombotic and fibrosis.

However, the side effects of these drugs are increasing. Many of these treatments do not pass the clinical trials. The failure rates of solid phase oligonucleotide synthesis drugs are high. For every clinical trial, the market puts in massive capital. These failures and side effects can affect oligonucleotide synthesis market growth. Also, the revenue rates of the market are restricted. Long term side effects are major factors that decline demand. 

  • The market challenges¬†

The poor delivery systems supply oligonucleotide synthesis drugs. The application of gene therapy is ruing tumour cells. In both clinical and experimental forms, these drugs are effective. However, the poor channel to supply these drugs is a significant challenge. Supplying these to the target customer is inefficient.

The poor delivery channels are a major cause of this channel. The market needs the development of delivery vendors. Also, it will ensure the safe and secure delivery of oligonucleotide synthesis drugs. Further, the fewer technologies to engage therapeutic drugs are another challenge. These challenges can hamper oligonucleotide synthesis market growth. 

  • Cumulative growth analysis¬†

The oligonucleotide synthesis market report shows a surging growth trend. The factors that lead to high growth are governmental investments and health industry expansion. These factors expand and develop the oligonucleotide synthesis market. The antisense oligonucleotide market is drug-based. 

It is a profitable segment of the market. The demand for these drugs is immense in emerging economies. Further, the adoption rate of this component is highest in hospitals. However, the barriers of the market are side effects and poor delivery channels. These challenges are expected to impede growth. Still, the overall growth rate is substantial with vast opportunities in emerging economies. 

  • Value chain analysis¬†

North America is accounted for maximum market shares. The importance of life science is high in North America. Improving health care application is leading to the effective use of oligonucleotide synthesis. The tools to produce drugs are high end in oligonucleotide synthesis market. Also, investments in the health industry are in millions.

The personalized therapeutic is bring great opportunities. Top leaders in the market take care of all the market operations well. The profitable key players make new developments and product launches. Also, there are only fewer barriers in North America. It leads to high growth in regions such as US and Canada. 

Segment overview 

By product 

  • Primers¬†

  • RNA Oligos

  • Other Synthesized Oligos

  • Probes

  • DNA Oligos

By type 

  • Predesigned oligos¬†

  • Customize oligos¬†

  • Equipment¬†

  • Reagent¬†

By application 

  • Research application¬†

  • Sequencing¬†

  • PCR¬†

  • Diagnostic application¬†

By type 

  • CpG oligonucleotide synthesis therapy¬†

  • Antisense oligonucleotide synthesis

  • RNA oligonucleotide synthesis

By disease type 

By end-user 

  • Academic research¬†

  • Hospitals¬†

  • Pharmaceuticals¬†

  • Diagnostic laboratory¬†

By region 

  • Asia pacific¬†

  • Europe¬†

  • North America¬†

  • Middle East Africa¬†

  • Latin America¬†

Competitive landscape 

The competition in the oligonucleotide synthesis market is expected to increase. Various market acquisitions will happen in the market. Expanding product portfolio is a key strategy of key players. 

Regional analysis 

The regional segment of the oligonucleotide synthesis market has three major players. Asia Pacific, Europe and North America contribute the highest for the oligonucleotide synthesis market. North America will dominate the oligonucleotide synthesis in the forecast period. Also, the developed health infrastructure is the major cause of high demand. Effective use of oligonucleotide synthesis to cure chronic illness will enhance the growth rate.

Further, Asia Pacific is the next largest market with rapid growth. Developing an economy and government support are two factors that stir demand. ‚ÄúGenome India project‚ÄĚ will create massive scope in Asia pacific. The¬†oligonucleotide synthesis market collects thousands of genetic samples for clinical trials. All these will bring high growth prospects in the regional market.¬†

The key players of the oligonucleotide synthesis market are 

  • Thermo Fisher Scientific Inc.

  • Adtbio, Merck - Co. Inc.

  • Bio-Synthesis Inc.

  • Eurofins Genomics

  • GE Healthcare

  • Horizon Discovery Ltd

  • Agilent Technologies

  • Genscript

  • Kaneka Eurogentec SA

  • Nitto Denko Avecia

  • Integrated DNA Technologies Inc.

  • BioAutomation

  • LGC Biosearch Technologies

  • Sarepta therapeutics

  • Agilent Technologies
  • Recent developments

    • In June 2022, Agilent Technologies, Inc., announced the launch of their new New Oligonucleotide Analysis Software for Biopharma Research.

    • In March 2022, findings from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) were released by Biogen Inc., and Ionis Pharmaceuticals, Inc.

    • In February 2021, in partnership with AstraZeneca, Novartis, Exactmer, and UK Research & Innovation, CPI announced the beginning of a project in the Medicines Manufacturing Innovation Centre that intends to revolutionize the production of oligonucleotides.

    Market overview 

  • Market overview highlights¬†

  • Analysis based upon COVID 19

  • Explanation upon the Market Dynamics

  • Value chain analysis

  • Market segmentation overview

  • The regional analysis

  • Competitive landscape analysis

  • Recent Developments

  • Report Scope:

    Report Attribute/Metric Details
      Market Size   USD 27,109.8 million
      CAGR   16.5%
      Base Year   2021
      Forecast Period   2022-2030
      Historical Data   2020
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Product, Type, Application, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Thermo Fisher Scientific, Inc., Adtbio, Merck - Co., Inc., Bio-Synthesis Inc., Eurofins Genomics, GE Healthcare, Horizon Discovery Ltd, Agilent Technologies, Genscript, Kaneka Eurogentec SA, Nitto Denko Avecia, Integrated DNA Technologies, Inc., BioAutomation, LGC Biosearch Technologies, Sarepta therapeutics, Agilent Technologies
      Key Market Opportunities   The Existence of Better health care infrastructure and increasing usage of oligonucleotides by pharmaceutical companies of the region and many strategic collaborations among the players in the market.
      Key Market Drivers   New product launches and R&D Amongst major key Players

    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Oligonucleotide Synthesis Market is projected grow at approximately 16.5% CAGR during the assessment period.

    GE Healthcare (U.S.), Integrated DNA Technologies, Inc. (U.S), Agilent Technologies Inc. (U.S.), Bioautomation Corporation (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Eurofins Genomics (Germany), L.G.C Biosearch Technologies (U.S.), Nitto Denko Avecia Inc. (Japan), and Eurogentec S.A (Belgium), are some of the major players operating in the oligonucleotide synthesis market.

    North America holds the largest share in the Global Oligonucleotide Synthesis Market, followed by Europe and the Asia Pacific, respectively.

    Technological advancements, rising disposable income levels of patients, huge investments from big pharmaceutical companies in oligonucleotide synthesis for drug development, CMO’s involvement in manufacturing therapeutic oligonucleotides, and wide application areas offered by the oligonucleotides.

    Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global oligonucleotide synthesis market adopt to gain a larger competitive advantage.